A double-blind study to assess the efficacy and safety of clazosentan in reducing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223314

Enrollment

220

Registered

2016-09-05

Start date

2016-12-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal subarachnoid hemorrhage (aSAH)

Interventions

investigational material(s) Generic name etc : ACT-108475 INN of investigational material : clazosentan Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Invest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients treated by endovascular coiling WFNS GradeI - IV Fisher group 3

Exclusion criteria

Exclusion criteria: Presence of cerebral vasospasm seen prior to the endovascular coiling etc.

Design outcomes

Primary

Measure	Time frame
efficacy The occurrence of the morbidity/mortality event. DSA and CT image will be taken. The relationship between each event and cerebral vasospasm will be finally judged by Event Review Committee and Image Review Comittee.	—

Secondary

Measure	Time frame
safety efficacy The occurrence of each component of the morbidy/mortality events GOSE, mRS, MMSE morbidity/mortality event: The appropriateness of the events will be confirmed by Event Review Committee and Image Review Comittee. GOSE, mRS, MMSE: Assessed by investigators.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026